Compare Divis Laboratories with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs NOVARTIS - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES NOVARTIS DIVIS LABORATORIES/
NOVARTIS
 
P/E (TTM) x 34.6 479.2 7.2% View Chart
P/BV x 6.6 27.8 23.9% View Chart
Dividend Yield % 0.9 1.6 55.9%  

Financials

 DIVIS LABORATORIES   NOVARTIS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
NOVARTIS
Mar-18
DIVIS LABORATORIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,639758 216.3%   
Low Rs1,115579 192.6%   
Sales per share (Unadj.) Rs186.3228.4 81.6%  
Earnings per share (Unadj.) Rs51.031.7 160.6%  
Cash flow per share (Unadj.) Rs57.332.8 175.0%  
Dividends per share (Unadj.) Rs16.0010.00 160.0%  
Dividend yield (eoy) %1.21.5 77.7%  
Book value per share (Unadj.) Rs261.8297.1 88.1%  
Shares outstanding (eoy) m265.4724.69 1,075.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.42.9 252.5%   
Avg P/E ratio x27.021.1 128.3%  
P/CF ratio (eoy) x24.020.4 117.7%  
Price / Book Value ratio x5.32.2 233.8%  
Dividend payout %31.431.5 99.7%   
Avg Mkt Cap Rs m365,59216,505 2,215.0%   
No. of employees `00011.80.7 1,773.5%   
Total wages/salary Rs m5,4231,445 375.2%   
Avg. sales/employee Rs Th4,175.18,441.3 49.5%   
Avg. wages/employee Rs Th457.72,163.6 21.2%   
Avg. net profit/employee Rs Th1,141.81,173.1 97.3%   
INCOME DATA
Net Sales Rs m49,4635,639 877.2%  
Other income Rs m1,5561,718 90.6%   
Total revenues Rs m51,0197,357 693.5%   
Gross profit Rs m18,718-63 -29,949.4%  
Depreciation Rs m1,68925 6,675.9%   
Interest Rs m3555 63.3%   
Profit before tax Rs m18,5511,575 1,177.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023792 634.6%   
Profit after tax Rs m13,527784 1,726.3%  
Gross profit margin %37.8-1.1 -3,414.3%  
Effective tax rate %27.150.3 53.9%   
Net profit margin %27.313.9 196.8%  
BALANCE SHEET DATA
Current assets Rs m46,5019,522 488.4%   
Current liabilities Rs m8,4683,296 256.9%   
Net working cap to sales %76.9110.4 69.6%  
Current ratio x5.52.9 190.1%  
Inventory Days Days13137 357.2%  
Debtors Days Days8628 302.0%  
Net fixed assets Rs m25,79746 56,080.0%   
Share capital Rs m531123 430.2%   
"Free" reserves Rs m68,9627,213 956.1%   
Net worth Rs m69,4937,336 947.2%   
Long term debt Rs m00-   
Total assets Rs m80,38311,105 723.8%  
Interest coverage x531.029.5 1,801.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.5 121.2%   
Return on assets %16.97.6 223.4%  
Return on equity %19.510.7 182.2%  
Return on capital %26.722.2 120.3%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23861 68,048.8%   
Fx outflow Rs m12,4053,630 341.7%   
Net fx Rs m28,833-3,570 -807.7%   
CASH FLOW
From Operations Rs m9,5431,610 592.8%  
From Investments Rs m-6,854687 -997.7%  
From Financial Activity Rs m-2,459-2,677 91.9%  
Net Cashflow Rs m230-380 -60.5%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.8 2.0 590.0%  
FIIs % 19.0 1.6 1,187.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 21.5 80.0%  
Shareholders   31,796 41,647 76.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   WYETH LTD  IPCA LABS  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Oct 18, 2019 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - CIPLA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS